# Thomas, McNerney & Partners

> Thomas, McNerney & Partners is a VC fund backing Biotechnology. See 36 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Stamford, United States
- Total investments: 36
- Last investment: Mar 2017
- Lead investor: 36%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/3070249
- X (Twitter): http://twitter.com/thomasmcnerney
- Website: http://www.tm-partners.com

Thomas, McNerney & Partners is a health care venture capital firm with approximately $600 million under management focused on investing in life science and medical technology companies. The firm targets investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors as well as in other areas utilizing medicaltechnology innovation. Companies developing therapeutic products for life threatening or costly, chronic conditions are of particular interest.Thomas, McNerney & Partners invests in companies at all stages of their development. In addition to helping entrepreneurs launch companies with seed and early stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization. The partnership also is involved in spinning out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies as well as recapitalizations.

## Contacts

5 contacts available for Thomas, McNerney & Partners. Shizune tracks 1 team members at Thomas, McNerney & Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/thomas-mcnerney-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 16 | 44% |
| Health Care | 15 | 42% |
| Medical | 7 | 19% |
| Pharmaceutical | 7 | 19% |
| Therapeutics | 6 | 17% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 10 | 28% |
| Funding Round | 6 | 17% |
| Series A | 4 | 11% |
| Series C | 4 | 11% |
| Series D | 3 | 8% |

8 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| James Thomas | Partner | 6 | https://shizune.co/investors/profile/james-e-thomas |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| VertiFlex | VertiFlex, Inc., a medical device company, provides minimally invasive and motion preserving spinal surgery technologies in the United States and internationally. The company offers superion interspinous spacer, a percutaneous titanium implant that fits between the spinous processes in the lumbar spine. Its Superion is a motion-preservinginterspinous spacer for the treatment of moderate spinal stenosis.Vertiflex Inc was founded in 2005 and is headquartered in California, USA. | $45.3M |  | Mar 27, 2017 |  |
| Torax Medical | Torax Medical, Inc., a clinical stage medical device company, develops an implantable device for the treatment of gastroesophageal reflux disease. It provides treatments for digestive diseases, including acid reflux. The company was founded in 2002 and is based in Shoreview, Minnesota. | $25M | Series E | Jul 26, 2016 |  |
| Invitae | Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, fasterturnaround time, and a lower price than most single-gene diagnostic tests today.What’s our plan? It takes three steps:--Make genetic testing more affordable and accessible than ever before.--Build a secure and trusted genome management infrastructure.--Design a new global community for sharing genetic information to advance science and medicine.Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people. | $120M | Series F | Oct 13, 2014 |  |
| SG Biofuels | SGB is a fully-integrated bioenergy crop company using molecular breeding and biotechnology to develop and produce elite hybrid seeds of Jatropha as a low-cost feedstock for biodiesel, bio-jet fuel, and specialty chemicals. With the largest and most diverse library of Jatropha genetic material, SGB is turning the opportunities of Jatropha intoreality through a world-class leadership team, leading-edge science and genetics, and expertise in agronomy and plantation management.SGB has been named one of the Top 5 Renewable Jet Fuel Supply Chain Companies in the World by The Carbon War Room (2011), one of the Top 50 Companies in Bioenergy for three consecutive years (2009, 2010, and 2011), and the 2010 Feedstock Domestication Project of the Year by Biofuels Digest and one of the Top 200 Going Green Private Companies in the World by Always On. | $11M | Series C | Sep 09, 2014 |  |
| Auspex Pharmaceuticals | Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. The company's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardivedyskinesia, and Tourette syndrome, as well as other orphan indications. | $20M | Series E | Jan 08, 2014 |  |
| Auspex Pharmaceuticals | Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. The company's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardivedyskinesia, and Tourette syndrome, as well as other orphan indications. | $25M | Series D | Nov 08, 2012 |  |
| Cebix | Cebix is focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The role of C-peptide will also be explored in type 1 diabetic nephropathy and retinopathy. | $33.2M | Series B | Oct 18, 2012 |  |
| Tioga Pharmaceuticals | Tioga Pharmaceuticals, Inc. develops therapies for the treatment of gastrointestinal diseases. Its product includes asimadoline, an orally administered small molecule therapeutic for the treatment of irritable bowel syndrome and functional dyspepsia. The company was founded in 2005 and is based in San Diego, California. |  | Series B | Apr 12, 2012 |  |
| SG Biofuels | SGB is a fully-integrated bioenergy crop company using molecular breeding and biotechnology to develop and produce elite hybrid seeds of Jatropha as a low-cost feedstock for biodiesel, bio-jet fuel, and specialty chemicals. With the largest and most diverse library of Jatropha genetic material, SGB is turning the opportunities of Jatropha intoreality through a world-class leadership team, leading-edge science and genetics, and expertise in agronomy and plantation management.SGB has been named one of the Top 5 Renewable Jet Fuel Supply Chain Companies in the World by The Carbon War Room (2011), one of the Top 50 Companies in Bioenergy for three consecutive years (2009, 2010, and 2011), and the 2010 Feedstock Domestication Project of the Year by Biofuels Digest and one of the Top 200 Going Green Private Companies in the World by Always On. | $17M | Series B | Jan 17, 2012 |  |
| InnoPharma | InnoPharma, LLC. Founded in 2005, is a privately held pharmaceutical research and development (R&D) company, based in Piscataway, New Jersey. | $15M | Series A | Dec 02, 2011 |  |

10 of 36 investments shown.

## Co-investors
- [Investor Growth Capital Limited](https://shizune.co/investors/profile/investor-growth-capital) — VC Fund, 5 deals together
- [H.I.G. Capital](https://shizune.co/investors/profile/hig-capital) — VC Fund, 4 deals together
- [Sofinnova Investments](https://shizune.co/investors/profile/sofinnova-ventures) — VC Fund, 3 deals together
- [The Vertical Group](https://shizune.co/investors/profile/the-vertical-group) — VC Fund, 3 deals together
- [Clarus Ventures](https://shizune.co/investors/profile/clarus-ventures) — VC Fund, 2 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Thomas, McNerney & Partners invest in?

Thomas, McNerney & Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Funding Round stage. Most of the 36 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Thomas, McNerney & Partners?

Public channels for Thomas, McNerney & Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Thomas, McNerney & Partners?

The team at Thomas, McNerney & Partners includes James Thomas (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co